Prolactinomas are the most common pituitary adenomas (approximately 40% of cases), and
they represent an important cause of hypogonadism and infertility in both sexes. The …

Abstract Background Dopamine agonists (DAs) are the main treatment for patients with
hyperprolactinemia and prolactinomas. Recently, an increasing number of reports …

While the prevalence of hyperprolactinemia under antidepressants is very low, its
prevalence under antipsychotics, particularly of the first generation, is high. Antipsychotics …

Hyperprolactinemia may be associated with psychiatric disorders in the context of two
scenarios: antipsychotic-induced hyperprolactinemia and psychiatric disorders arising from …

The dopaminergic treatment represents the primary treatment in prolactinomas, which are
the most common pituitary adenomas and account for about 40% of all pituitary tumours with …

Patients with pituitary neuroendocrine tumors (PitNETs) often experience neuropsychiatric
disorders due to factors such as hormonal imbalances, and inadequate management of …

Context In patients treated with antipsychotics, the rare occurrence of a macroprolactinoma
represents a therapeutic challenge. Objective Our aim was to evaluate the efficacy and …

In this report, we describe a female patient with both prolactinoma and psychotic disorder
who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist …

Cabergoline, a dopamine agonist agent, is commonly used in the treatment of
hyperprolactinemia, Parkinson's disease, restless leg syndrome, and antipsychotic-induced …

Many antipsychotic (AP) medications work by reducing dopamine levels. As
hyperdopaminergia is known to cause psychosis, antipsychotics work to relieve these …